Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study

    January 2023 in “ Curēus
    Remi K. Hamel, Ling Chen, Cailin O’Connell, Caroline Mann
    Image of study
    TLDR Low-dose naltrexone may help reduce redness in certain scalp conditions.
    This study investigated the use of low-dose naltrexone (3 mg daily) as adjunctive therapy for frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) in 26 patients over one year. Results showed a significant decrease in erythema at 12 months compared to baseline, with a mean reduction of 0.93 on a 0-3-point scale (p<0.0001). However, there were no significant changes in pruritus, burning/pain, or scalp involvement. The study suggests that low-dose naltrexone may be beneficial for treating erythema in FFA and LPP, though further research is needed due to limitations such as small sample size and concurrent medications.
    Discuss this study in the Community →

    Research cited in this study

    13 / 13 results

    Related Community Posts Join

    3 / 3 results

    Similar Research

    5 / 139 results